Khiron Life Sciences Corp V.KHRN.H

RE:RE:RE:The Dales Report - Full Interview with Chris Naprawa

[Benedictus]

kyle I wanted to give you the benefit of the doubt, as I always welcome criticism of my long positions since I can re-evaluate my position from a different viewpoint, but I now believe you are simply another troll stockhouse basher cherry picking only one sided analysis in an attempt to grind down longterm holders patience. 

as I've already stated: a 2 year cash runway in this current market is most mj companies dream right now. This cash horde only adds to Khiron's competitive advantage in Lat Am. 

the 'dreary state of sales' is merely due to the clinical model not coming online until early 2020. The sales ramp next year will show just what khrn has built over the last 18 months. If you've truly done your dd on khiron you would already know the kuida and recreational lines are not the bread and butter of this company. The medical approach will be the foundation of their sales because of consumer demand and the tremendous consistent revenue stream it will provide.

"low barrier game" - care to provide more detail on that? if you truly listen to any conf calls from companies in this sector, you'd know this is not at a low barrier game, especially with current access to capital, legality issues and ongoing ever changing regulatory environments...  Care to point me to another Lat Am company with the mgt team, cash horde, and multi-pronged approach to revs as khiron? 

any frustration I have is moreso that the market is throwing the baby out with the bathwater and punishing low valuation US companies as much or more than the high valuation CAD companies. But that's what makes a market and I've seen this happen time and again in other sectors. We are still in the very early days in this burgeoning sector and khiron is positioning itself very well imo. 

where I will agree with you is that I'm not ruling out the possibility of lower lows than we've already seen. With tax loss selling season and the big dogs like canopy and aurora releasing atrocious earnings, there remains the possibility of more blood in the streets but from a relative strength standpoint, traders can only stretch the rubber band so far before a serious relief rally occurs. All imo